Pricing Log in Create free account

Atara Biotherapeutics, Inc. (ATRA) vs Cellectis S.A. (CLLS)

Atara Biotherapeutics, Inc. and Cellectis S.A. are both Biotechnology companies. Atara Biotherapeutics, Inc. and Cellectis S.A. are of similar size ($92.6M and $90.4M). Cellectis S.A. grew revenue faster over the last twelve months: 0.61% against −96.7%. Cellectis S.A. has the higher net margin (−102.3% vs −269.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Cellectis S.A. leads on 8 and Atara Biotherapeutics, Inc. on 7.

Valuation

Metric ATRA CLLS Biotechnology median
P/E n/m n/m 8.68
P/S 22.91 1.99 10.29
P/B n/m 3.09 2.40
Price to free cash flow n/m n/m 20.52
EV/EBITDA n/m n/m 0.68
EV/Sales 21.32 0.53 10.15
Earnings yield (12.50%) (51.91%) (28.86%)
Free cash flow yield (14.82%) (36.43%) (22.44%)

Profitability

Metric ATRA CLLS Biotechnology median
Gross margin 91.38% 100.00% 65.16%
Operating margin (229.67%) (90.88%) 0.00%
Net margin (269.42%) (102.34%) 0.00%
Free cash flow margin (353.49%) (68.63%) 0.00%
Return on equity 46.33% (94.54%) (56.66%)
Return on assets (57.62%) (21.02%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ATRA CLLS Biotechnology median
Revenue growth (TTM) (96.72%) 0.61% 5.64%
EPS growth (last fiscal year) 122.52% (63.41%) 30.08%
Revenue growth, 5-year CAGR — (0.70%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ATRA CLLS Biotechnology median
Debt to equity 0.00 1.79 0.00
Current ratio 1.98 1.37 4.72
Net debt to EBITDA (0.22) 9.54 0.96

Dividend

Metric ATRA CLLS Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric ATRA CLLS Biotechnology median
Market cap 92.64m 90.41m 150.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack